Error loading player: No playable sources found
2105
Colorectal Diseases I
Date
May 18, 2024
SOCIETY: SSAT
Presentations:
| ELEVATED RED CELL DISTRIBUTION WIDTH TO PLATELET RATIO IS ASSOCIATED WITH LOW GRADE DYSPLASIA IN IBD |
| TREATMENT OF STAGE IV EARLY-ONSET COLORECTAL CANCER: A COMPARATIVE ANALYSIS |
| RANDOMIZED CONTROLLED TRIAL ON ORAL ADMINISTRATION OF LACTOBACILLUS CASEI DG FOR 8 WEEKS AFTER ILEOSTOMY CLOSURE (MICROBIOTA AND IMMUNE (MICROENVIRONMENT IN POUCHITIS.-MEP1- NCT03136419). |
| IMPACT OF END-ILEOSTOMY VERSUS ILEAL POUCH-ANAL ANASTOMOSIS ON GRAFT-SURVIVAL FOLLOWING LIVER TRANSPLANTATION FOR PRIMARY SCLEROSING CHOLANGITIS |
| IMPACT OF TIME TO SURGERY ON OUTCOMES FOLLOWING LOW ANTERIOR RESECTION FOR RECTAL CANCER |
| TRENDS IN COST SHARING AND CANCER TREATMENT MODALITY UTILIZATION AMONG COMMERCIALLY INSURED PATIENTS WITH GASTROINTESTINAL CANCER |
| RCMIX MODEL BASED ON PRE-NEOADJUVANT THERAPY T2WI IMAGING CAN PREDICT THE T-STAGE DOWNSTAGING IN MRI-CT4 STAGE RECTAL CANCER PATIENTS |
| MESENTERIC LENGTHENING TECHNIQUES FOR ILEOANAL POUCH CONSTRUCTION: WHAT TO DO WHEN THE POUCH WON'T REACH |
| IMMUNOREACT 13: IMMUNE SURVEILLANCE MARKERS IN THE CLINICAL MANAGEMENT OF STAGE II RECTAL CANCER |
| DOES MESORECTAL FASCIA INVOLVEMENT (MRF) AFFECT THE RESPONSE TO TNT IN LOCALLY ADVANCED RECTAL CANCERS? |
| ONCOLOGIC OUTCOMES AFTER POUCH EXCISION: IS THERE A DIFFERENCE BETWEEN IBD AND FAP POUCH NEOPLASIA? |
| IS THERE A ROLE FOR TOTAL NEOADJUVANT TREATMENT IN EARLY-STAGE RECTAL CANCER |
| METASTASECTOMY FOR STAGE IV COLORECTAL CANCER IS ASSOCIATED WITH IMPROVED SURVIVAL - BUT NOT ALL PATIENTS HAVE ACCESS TO IT |
| UNRAVELING THE CELLULAR MECHANISMS OF INTESTINAL ANASTOMOTIC HEALING: THE ROLE OF THE SEROSA |
Moderators
Universita Vita Salute San Raffaele
University of Washington
Oregon Health & Science Univ
Speakers
Azienda Ospedale Universita Padova
The Ohio State Wexner Medical Center
General
Tracks
Related Products
IMMUNOREACT 13: IMMUNE SURVEILLANCE MARKERS IN THE CLINICAL MANAGEMENT OF STAGE II RECTAL CANCER
BACKGROUND Stage II colorectal cancer should undergo adjuvant therapy only in the presence of risk factors and vascular, lymphatic, and perineural invasion (VELIPI) are risk factors for recurrence after surgery…
IMMUNOREACT 3: PERITUMORAL IMMUNE MICROENVIRONMENT MARKERS AS PREDICTORS OF RECURRENCE AFTER ADJUVANT THERAPY IN LOCALLY ADVANCED RECTAL CANCER
BACKGROUND: Adjuvant therapy after rectal cancer surgery is indicated in T4N0 or any T and nodal metastasis and/or risk factors for recurrences…
Best of Colorectal Diseases
SOCIETY: SSAT
